Clinical trials: Six-minute Walk Test
Cardiac Rehabilitation
The Healthy Heart Study
The long-term goal of this research is to improve patient-centered outcomes in patients with coronary heart disease (CHD), the leading cause of death in the world.
- Trial name
- NCT02105246
- Testing
- Referral to home-based cardiac rehab, Referral to center-based cardiac rehab
- Where
- United States
- Volunteers
- 1,154 people
- Sponsor
- University of California, San Francisco
Lymphangioleiomyomatosis
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis
- Trial name
- NCT01059318
- Testing
- Everolimus
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
Cardiometabolic Disease and Pulmonary Hypertension
This study will investigate if metformin can help people with obesity and high pressures inside their lung blood vessels. Metformin is approved by the U.S.
- Trial name
- NCT03349775
- Testing
- Metformin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Heart Failure
LifeVest Trends Validation Protocol
This study will evaluate the accuracy of data on body position, daily activity, heart rate, 6-minute walk test, and a health survey collected by the wearable cardioverter defibrillator (WCD).
- Trial name
- TRENDS (NCT02149290)
- Testing
- Trends-equipped LifeVest 4000
- Where
- 21 sites in United States, Austria and 1 more
- Volunteers
- 198 people
- Sponsor
- Zoll Medical Corporation
Heart Failure
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
In the U.S., 5.7 million people have heart failure (HF), 915,000 new cases are diagnosed each year, and both incidence and prevalence are increasing due to the aging of the population and to better survival from ischemic heart…
- Trial name
- NCT03615469
- Testing
- Transcutaneous electrical stimulation, Neuromuscular electrical stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Pulmonary Arterial Hypertension
Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
Pulmonary hypertension is characterized by an increase in the pressures in the blood supply to the lungs greater than a mean pressure of 25mmHg and a concomitant increase in overall pulmonary vascular resistance (PVR).
- Trial name
- NCT02734953
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Oximetry
The Accuracy of Smartphone Pulse Oximetry in Patients Visiting an Outpatient Pulmonary Function Lab for a 6-Minute Walk Test
The primary aim of this research is to determine the accuracy of smartphone pulse oximeters in detecting blood oxygen saturations, episodes of desaturations, and heart rate by comparing results to a Masimo© hospital-grade pulse…
- Trial name
- NCT03534271
- Testing
- iPhone with Kenek Edge and Samsung S8
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Rush University Medical Center
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
PMV, Exercise Endurance
Does Endurance Improve With the Use of Passy-Muir Valve for Patients With Tracheostomy?
The purpose of this study is to determine if the use of the Passy-Muir Valve improves endurance for patients in the Long Term Acute Care setting as measured with the Six- Minute Walk Test.
- Conditions
- PMV, Exercise Endurance, Tracheostomy
- Trial name
- NCT04941456
- Testing
- Open Tracheostomy, PMV in place
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Gaylord Hospital, Inc
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks…
- Trial name
- PERFECT (NCT03496623)
- Testing
- Inhaled treprostinil solution
- Where
- 76 sites in United States, Argentina and 2 more
- Volunteers
- 188 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg…
- Trial name
- NCT01979952
- Testing
- Nintedanib
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study.
- Trial name
- NCT01560637
- Testing
- UT-15C (treprostinil diolamine)
- Where
- 153 sites in United States, Argentina and 21 more
- Volunteers
- 471 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
The objectives of this study are to evaluate the safety of RT234 and the effects of RT234 on exercise capacity as assessed by Cardiopulmonary Exercise Testing (CPET) and six minute walk testing (6MWT) as well as exertional…
- Trial name
- VIPAH-PRN_2B (NCT04266197)
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
- Where
- 26 sites in United States
- Volunteers
- 42 people
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02630316
- Testing
- Inhaled Treprostinil
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis
- Trial name
- NCT05497284
- Testing
- LTP001, Standard of Care (SoC)
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals